During the consultation on the draft guidance Janssen, the manufacturer of the drug, submitted further information for the committee to consider.
This included a revised patient access scheme which involves providing the drug to the NHS at a discounted price, further information on which patients would benefit most and clarification on how many patients could receive the drug.
These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS.
More top news
Figures uncovered by a Freedom of Information request reveal one university leader received £623,000 in 2013/14.
Tens of thousands of students are not achieving their potential in state schools, a highly-critical Ofsted report has said.
Lawyers for Mohammed Emwazi's father have told ITV News there's no evidence his son is IS killer 'Jihadi John' as "his face is covered".